A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutatio

A Phase 3 Study of Sosimerasib in Combination With IN10018 Versus Standard Therapy for First Line Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation is a phase 3, randomised interventional study registered as NCT07833202 by Shanghai Jeyou Pharmaceutical Co., Ltd., with a registry enrolment figure of 416 participants, started 2026-10 and due to reach its primary completion in 2029-04. Interventions recorded: Sosimerasib in combination with IN10018; Tislelizumab + Carboplatin + Pemetrexed. Conditions listed: NSCLC. Primary outcome: Progression-Free Survival (PFS). Lung eligibility wording from the registry: "Histologically or cytologically documented Stage IIIB or IIIC NSCLC disease not amenable for surgical resection or definitive chemoradiation or Stage IV Non-squamous NSCLC disease". Sites: China. No results are recorded here; the registry entry is the source.